CY1114650T1 - USE OF PRE-MEDICINES FOR OPTICAL INTELLIGENCE ADMINISTRATION - Google Patents

USE OF PRE-MEDICINES FOR OPTICAL INTELLIGENCE ADMINISTRATION

Info

Publication number
CY1114650T1
CY1114650T1 CY20131101064T CY131101064T CY1114650T1 CY 1114650 T1 CY1114650 T1 CY 1114650T1 CY 20131101064 T CY20131101064 T CY 20131101064T CY 131101064 T CY131101064 T CY 131101064T CY 1114650 T1 CY1114650 T1 CY 1114650T1
Authority
CY
Cyprus
Prior art keywords
medicines
optical intelligence
administration
intelligence administration
optical
Prior art date
Application number
CY20131101064T
Other languages
Greek (el)
Inventor
Laura Rabinovich-Guilatt
Grégory Lambert
Original Assignee
Novagali Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06290902A external-priority patent/EP1864668B1/en
Application filed by Novagali Pharma S.A. filed Critical Novagali Pharma S.A.
Publication of CY1114650T1 publication Critical patent/CY1114650T1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Σύνθεση για χρήση στην θεραπεία μιας οφθαλμικής πάθησης ή ασθένειας ενός ανθρώπινου όντος ή ενός ζώου που την έχει ανάγκη, που περιλαμβάνει χορήγηση με επιθετικά μέσα, κατά προτίμηση με ενδοφθάλμια ένεση, τουλάχιστον ενός προ-φαρμάκου ενός στεροειδούς.Composition for use in the treatment of an eye disease or disease of a human being or animal in need thereof, comprising administering by aggressive means, preferably by intraocular injection, at least one prodrug of a steroid.

CY20131101064T 2006-06-01 2013-11-27 USE OF PRE-MEDICINES FOR OPTICAL INTELLIGENCE ADMINISTRATION CY1114650T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06290902A EP1864668B1 (en) 2006-06-01 2006-06-01 Use of prodrugs for ocular intravitreous administration
EP10177382.8A EP2319517B1 (en) 2006-06-01 2006-06-01 Use of prodrugs for ocular intravitreous administration

Publications (1)

Publication Number Publication Date
CY1114650T1 true CY1114650T1 (en) 2016-12-14

Family

ID=49724909

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20131100153T CY1113750T1 (en) 2006-06-01 2013-02-20 USE OF PRE-MEDICATIONS FOR EYE INTRODUCTION
CY20131101064T CY1114650T1 (en) 2006-06-01 2013-11-27 USE OF PRE-MEDICINES FOR OPTICAL INTELLIGENCE ADMINISTRATION

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20131100153T CY1113750T1 (en) 2006-06-01 2013-02-20 USE OF PRE-MEDICATIONS FOR EYE INTRODUCTION

Country Status (4)

Country Link
CY (2) CY1113750T1 (en)
ES (1) ES2437160T3 (en)
PT (1) PT2319517E (en)
SI (1) SI2319517T1 (en)

Also Published As

Publication number Publication date
ES2437160T3 (en) 2014-01-09
SI2319517T1 (en) 2014-01-31
CY1113750T1 (en) 2016-06-22
PT2319517E (en) 2013-11-25

Similar Documents

Publication Publication Date Title
CY1122428T1 (en) THERAPEUTIC MANAGEMENT OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA WITH BISPECIFIC ANTIBODIES AGAINST CD3XCD19
DK2319517T3 (en) APPLICATION OF PRODRUGS TO OCULAR, INTRAVENOUS ADMINISTRATION
CY1120417T1 (en) METHODS TO REDUCE BASEFLOW LEVELS
CY1121125T1 (en) COMPOSITIONS FOR THE TREATMENT OF PAIN AND / OR INFLAMMATION
CY1116424T1 (en) ADENINIS PRODUCTION AS RISK RISK
CY1119649T1 (en) EXTREMELY FREEZING AND / OR TERMINATION OF SUBSTANTIAL-CONDITIONAL SUBSTANTIAL DRUG RELEASE
MA51617A (en) DRUG DELIVERY MECHANISM
CY1118731T1 (en) ALVIGLUTIDIS PHARMACEUTICAL COMPOSITIONS
CY1120879T1 (en) MULTIPLE INGREDIENT BIOACTIVE INTALCALINE RING
BR112012025581A2 (en) sustained release reservoir implants for intracameral drug delivery
CY1113766T1 (en) INDOLIDONES PRODUCTS FOR THE TREATMENT OR PREVENTION OF DISEASES
CY1116927T1 (en) TETROHYDROCANNABINOL PRODUCTS, COMPOSITIONS CONTAINING TETHYROCANNABINOL PRODUCTS AND METHODS OF USE
EA200901211A1 (en) ANTIGENS OF C5 PROTEIN AND THEIR APPLICATION
CY1117603T1 (en) LIXISENATIDE AS AN ADDITION TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES
DK2148670T3 (en) Titration of tapentadol
CY1121865T1 (en) OPHTHALMOLOGICAL COMPOSITIONS AND THEIR USE
AR057946A1 (en) FORMULATION OF SUSTAINED RELEASE ZONISAMIDE
CY1117854T1 (en) Peptide Pharmaceutical Form for Local Ophthalmic Use
CY1115136T1 (en) USE OF CHITOSANTS TO INCREASE Nail Growth Rate
AR088585A1 (en) A MEDICINAL PRODUCT TO TREAT THE PREVIOUS EYE DISEASE
HN2009003424A (en) (OXAZOLIDINON-5-IL-METIL) -2-TIOFEN-CARBOXAMIDAS REPLACED AND ITS USE IN THE FIELD OF THE SANGUINEA COAGULATION
CY1117671T1 (en) CLOSTRIDIUM DIFFICILE COMPLICATIONS FOR THERAPEUTIC DISEASE TREATMENT
AR061446A1 (en) USE OF 1,7-DIMETHYLXANTINE FOR THE MANUFACTURE OF A NON-ANIOIOUS PSYCHOANALEPTIC DRUG FOR THE TREATMENT OF A NEUROPSYCHIATRIC DISORDER
CY1114757T1 (en) OXAZINE PRODUCTS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS
EA202091533A1 (en) METHODS FOR TREATMENT OF DIABETES, HEPATITIS AND / OR INFLAMMATORY LIVER DISEASE